BNTC vs EDIT
BNTC: Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to potentially provide "one-shot" cures for genetic diseases. EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation.
Side-by-side fundamentals
| Metric | BNTC | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.44 | $2.78 | |
| Market cap as of 2026-07-23 | $396M | $421M | |
| Net margin as of 2026-07-23 | -20671.4% | -281.6% | EDIT higher |
| Gross margin as of 2026-07-23 | +100.0% | n/a | |
| Operating margin as of 2026-07-23 | -20714.3% | -281.3% | EDIT higher |
| ROE as of 2026-07-23 | -45.9% | -677.4% | BNTC higher |
| ROA as of 2026-07-23 | -44.0% | -58.3% | BNTC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 12.40 | BNTC lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.0% | |
| Revenue CAGR (3y) SEC XBRL | -93.0% | +27.1% | EDIT higher |
| Beta as of 2026-07-23 | 0.27 | 2.08 | |
| 1-year return as of 2026-07-22 close | +6.4% | -8.3% | BNTC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.